Cohance Lifesciences Limited has announced that a meeting of its Board of Directors is scheduled for Tuesday, May 12, 2026. The primary objective of this session is to review and approve the company’s audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026.
Upcoming Board Meeting
Cohance Lifesciences, formerly known as Suven Pharmaceuticals Limited, will hold a formal meeting of its Board of Directors on May 12, 2026. During this meeting, the board will deliberate upon the financial performance of the company for the fiscal year concluding on March 31, 2026. Investors and stakeholders can expect the release of the audited financial statements following the conclusion of this meeting.
Trading Window Update
In accordance with the company’s internal code of conduct regarding insider trading, the trading window for the company’s shares remains restricted. Designated persons and their immediate relatives are prohibited from trading during this period. The trading window will remain closed until May 14, 2026, ensuring compliance with market transparency standards following the disclosure of the year-end financial results.
Source: BSE
